Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prospective Blood Draw Clear all

Conditions: Upper Resp Tract Infection
Interventions: TEM-PCR URI Panel, SOC/Empiric Diagnosis; Diagnostic Test · Other
Lead sponsor: Diatherix Laboratories, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Athens, Alabama • Huntsville, Alabama

Conditions: Chronic Viral Hepatitis C, Monoclonal B-Cell Lymphocytosis
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pain, Anxiety
Interventions: Placebo Group, Buddhify Therapy; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 14 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Lymphoblastic Leukemia, Pediatric
Interventions: Observational only: Serology and flow cytometry for ALL cohort participants, Observational only: Infection rates; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Years to 31 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Chicago, Illinois • Grand Rapids, Michigan • Philadelphia, Pennsylvania + 3 more

Conditions: Spine Surgery, Intraoperative Hypotension, Tissue Perfusion
Interventions: Phenylephrine hydrochloride infusion, Norepinephrine bitartrate infusion; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreas Adenocarcinoma, Duodenal Adenocarcinoma, Ampullary Adenocarcinoma, Gallbladder Adenocarcinoma, Intra - and Extrahepatic Cholangiocarcinoma
Interventions: Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test; Procedure · Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Preterm Birth
Interventions: PreTRM test; Diagnostic Test
Lead sponsor: Ware Branch; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Murray, Utah • Ogden, Utah • Provo, Utah + 1 more

Conditions: Heart Failure
Interventions: In Vitro diagnostic tests; Device
Lead sponsor: Fujirebio Diagnostics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Detroit, Michigan

Conditions: Glaucoma
Interventions: (Cosopt®, prostaglandin); Drug
Lead sponsor: Indiana University; Other
Eligibility: 30 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Down Syndrome, Edwards Syndrome
Interventions: Maternal Blood Draw; Other
Lead sponsor: Progenity, Inc.; Industry
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 10
States / cities: Campbell, California • Long Beach, California • Denver, Colorado + 6 more

Conditions: Severe Sepsis, Septic Shock, Bacteremia
Interventions: Not listed
Lead sponsor: University of British Columbia; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Pleural Effusion
Interventions: Cathflo Activase, Talc Slurry Pleurodesis; Drug
Lead sponsor: Memorial Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Osteoarthritis, Intraoperative Bleeding
Interventions: Evicel Fibrin Spray; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Oak Park, Illinois

Conditions: Von Willebrand Diseases
Interventions: Von Willebrand Factor-Containing Product; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 66 Months and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function, Cell-free DNA, NGS
Interventions: Not listed
Lead sponsor: Devyser Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: San Diego, California • San Francisco, California • Atlanta, Georgia + 4 more

Conditions: Arteriovenous Fistula
Interventions: Lutonix DCB, Standard Balloon Angioplasty Catheter, Percutaneous Transluminal Angiography; Combination Product · Device · Procedure
Lead sponsor: C. R. Bard; Industry
Eligibility: 21 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 20 more

Conditions: High Grade Glioma
Interventions: Blood collections; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Baltimore, Maryland • St Louis, Missouri

Conditions: Hematologic Malignancies
Interventions: CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus; Device · Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Dry Eye
Interventions: Not listed
Lead sponsor: Toyos Clinic; Other
Eligibility: 22 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lymphoma
Interventions: Bleomycin Sulfate (BLM), Filgrastim (G-CSF), Recombinant Interferon Alfa, Carmustine, Cisplatin (CDDP), Cyclophosphamide, Cytarabine (ARA-C), Etoposide (VP-16), Idarubicin, Ifosfamide, Leucovorin Calcium, Melphalan, Methotrexate, Methylprednisolone, mitoxantrone hydrochloride (DHAD), Vincristine Sulfate, Peripheral Blood Stem Cell Transplantation, Radiation Therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 59 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Endocrine Therapy and a CDK 4/6 inhibitor; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ankle Arthritis
Interventions: Autologous Concentrated Plasma; Biological
Lead sponsor: Columbia Orthopaedic Group, LLP; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Eosinophilic Esophagitis
Interventions: Specimen Collection, Questionnaires; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer, Lymphedema
Interventions: Bilateral arm measurements, Body mass index (BMI), Quality of Life Questionnaire, Blood draw; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

TEM-PCR™ Prospective Clinical Utility Study

Study to Assess Monoclonal B-Cell Lymphocytosis in Individuals With Chronic Hepatitis C

A Prospective Study Investigating the Use of Relaxation Prior to Medical Procedures.

Vaccine Immune Recovery After Leukemia

Superiority of Phenylephrine Versus Norepinephrine in Complex Spine Surgery (SPiNeS)

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Prediction and Prevention of Preterm Birth (PREVENT-PTB Study)

Blood Collection of Patient Presenting in the ED and Prescribed a BNP

Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data

Non-Invasive Screening for Fetal Aneuploidy

Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

Use of a Novel Fibrin Sealant in Total Knee Arthroplasty

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population

Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae

Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

Single Center, Prospective, Randomized, Controlled, Non-significant Risk

Combination Chemotherapy in Treating Patients With Lymphoma

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

ACP for Local Application in Ankle Arthrodesis

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

Lymphedema Surveillance Study